In this episode of Rx for Biotech podcast, I speak with Philippe Chambon MD, PhD, CEO of EG 427, about how his company's HERMES technology platform could improve on the precision, durability and safety of gene therapy delivery. EG 427's lead candidate, EG110A, targets neurogenic bladder - a chronic condition linked to spinal cord injury, Parkinson's disease and multiple sclerosis - using a localized gene therapy designed to restore neuronal control with minimal side effects.

Airway Therapeutics is taking on one of the toughest challenges in medicine - helping premature infants breathe on their own. In this episode of Rx for Biotech, CEO Marc Salzberg shares how zelpultide alfa, an investigational, first-in-class biologic, could transform care for newborns with bronchopulmonary dysplasia (BPD) and unlock a new future for respiratory medicine.

In this podcast episode, Dr. Jay Lalezari, CEO of CytoDyn Therapeutics, discusses the company's progress in developing a novel immunotherapy that targets the CCR5 receptor, one of the master immune cell regulators. Jay reviews some of the early clinical data with leronlimab, a first-in-class investigational monocolonal antibody that targets the CCR5 receptor and is being studied in metasatic triple-negative breast cancer and colorectal cancer.

In this episode of Tc for Biotech, host Chris Leidli sits down with Thijs Spoor, CEO of Perspective Therapeutics, to unpack the future of radiopharmaceuticals for the treatment of cancer. This conversation goes beyond the science to explore the infrastructure and strategy that determines success in bringing target cancer therapies to patients.

In this episode of Rx for Biotech, host Chris Leidli sits down with Dr. Frank Bedu-Addo, CEO of PDS Biotechnology, to discuss how the company is reimagining immunotherapy with its proprietary Versamune® T-cell activating platform.

Early cancer detection doesn't have to mean invasive tests. In this podcast episode, we sit down with Jeff Bousfield, CEO of Nonacus Cancer Diagnostics, to explore how his UK-based company is revolutionizing precision cancer diagnostics with a powerful suite of non-invasive tools. Jeff shares the human story behind the science and why he believes the future of cancer care starts with precision diagnostics tools that are faster, less invasive, and more accessible to patients.

Metastatic pancreatic cancer remains one of the deadliest cancers, but a new approach is taking shape - and it's showing promise in early clinical studies. In this episode, Dan Schmitt, President and CEO of Actuate Therapeutics, shares how elraglusib, an investigational targeted therapy, may provide a new option for patients with metastatic pancreatic cancer. We explore the urgent unmet need and why Dan thinks this could be a turning point for one of oncology's toughest challenges.

In this podcast episode, Dr. Kilian Kelly, CEO of Cynata Therapeutics, discusses the future of regenerative medicine! Discover how mesenchymal stem cells (MSCs)—powerful cells that repair and regenerate tissues—are revolutionizing treatments for a range of diseases. Dr. Kelly shares insights on Cynata’s groundbreaking Cymerus™ platform and the exciting potential of MSC therapies.

Our guest in this podcast episode is lymphoma survivor and CAR-T cell therapy patient advocate, Brad Watts. In this episode, Brad shares his personal story battling lymphoma at the young age of 29 along with his experience receiving an innovative cell therapy. This field is transforming lives and Brad is living proof of this potential.

AI is transforming job search, recruiting and hiring practices. Our guest in this podcast episode is Steve Swan, Practice Leader at The Swan Group. Steve is an Executive Recruiter specializing in technology for the Pharmaceutical and Biotech Industry. In this episode Steve shares his insights on how AI is transforming the hiring process.

Gene therapy offers significant hope for treating sickle cell disease (SCD), a genetic disorder caused by a single mutation in the hemoglobin gene. Recent advancements have led to promising developments and FDA approvals, but challenges remain. In this podcast episode, gene therapy survivor, Jimi Olaghere, shares his journey and offers hope to others with his inspirational message and through his advocacy for patients in the sickle cell community.

In this podcast episode, hear from Diakonos Oncology President and Chief Operating Officer Jay Hartenbach, who provides an update on the company's innovative dendritic cell vaccine therapy designed to tackle some of the most challenging cancers, including glioblastoma and pancreatic cancer

Dr. Thomas Chen is a world-renowned neurosurgeon, Director of Surgical Neuro-Oncology at the University of Southern California, and the founder and CEO of NeOnc Technologies. In this podcast episode we discuss the company’s unique approach to treating glioblastoma and other aggressive brain cancers.

Our guest in this podcast episode is Sreekanth Gopi, a leader in generative AI and machine learning. Sreekanth has applied AI to fields as diverse as physiological monitoring, meditation, and even generating multi-track Indian classical music. He’s published award-winning research on EEG spectral analysis and adaptive quiz generation using large language models, participated in over 12 AI hackathons—winning two—and is now a Prompt Engineer at Morgan Stanley, where he fine-tunes cutting-edge LLM interactions for real-world applications. In this episode we explore how AI is redefining stress management and revolutionizing real-time physiological data applications. Tune in to learn about the world of generative artificial intelligence— and looking at its transformative potential in mental health and stress management.

Arvinas is a biotech company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. In this podcast episode, Dr. Randy Teel discusses the company's PROTAC protein degrader technology platform and its pipeline of clinical-stage assets, with a focus on vepdegestrant, the company's lead asset that is being co-developed together with partner Pfizer, for the treatment of women with early and locally advanced or metastatic ER+/HER2- breast cancer.

HLTH brings together all the ecosystem stakeholders each year to discuss the innovations that will help solve some of healthcare's biggest challenges. In this podcast episode, Noe Gutierrez, the Head of Commercial Operations at Genoplex, Inc., shares many of the key themes and insights from the biggest health tech conference of 2024.

Next Generation Gene Therapies is developing novel gene therapies for the treatment of many rare diseases. In this podcast episode, the company's Co-Founder and Chief Operating Officer, Guang Qu, discusses how the company's dual-functional vector tech platform is being used to target many diseases.

Immunotherapies continue to redefine treatment for many types of cancer and one of the first immunotherapies approved and used clinically as a therapeutic is Interleukin-2, or IL-2. Aulos Bioscience is an immuno-oncology company that has developed AU-007, a potential best-in-class IL-2, that improves on many of the other IL-2 products in development. In this episode, we discuss the promise of AU-007 with President and CEO, Aron Knickerbocker. Link to Interleukin-2 review article can be found here: https://www.nature.com/articles/s41587-022-01390-3

In this podcast episode, we discuss the importance of addressing health equity for the rare disease community with Tamar Thompson, Head of Corporate Affairs at Alexion, AstraZeneca Rare Disease. Tamar discussed her efforts to champion health policy, advocacy, equity, and awareness for rare diseases. Link to NMOSD video mentioned in episode: https://www.youtube.com/playlist?list=PLJQx_6LtucSB9GGeiWTycLm7wjK_LX0ZI

In this podcast episode, we sit down with Christopher Heery, the Chief Medical Officer at Arcellx to learn about the company's pipeline and lead cell therapy, anitocabtagene autoleucel, or anito-cel, that is in development for multiple myeloma. Multiple myeloma, like lymphoma and leukemia are types of cancer that start in your blood cells.